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Abstract Afatinib is an oral, ErbB family blocker, which
covalently binds and irreversibly blocks all kinase-compe-
tent ErbB family members. This phase II, open-label, single-
arm study explored afatinib activity in human epidermal
growth factor receptor 2 (HER2)-positive breast cancer
patients progressing after trastuzumab treatment. Patients
had stage IIIB/IV HER2-positive metastatic breast cancer,
with progression following trastuzumab or trastuzumab
intolerance and an Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2. Patients received 50 mg
afatinib once-daily until disease progression. Primary end-
point was objective response rate (Response Evaluation
Criteria in Solid Tumors 1.0), with tumor assessments every
8 weeks. Forty-one patients were treated. Patients had
received a median of three prior chemotherapy lines (range,
0–15) and 68.3% had received trastuzumab for[1 year. Four
patients (10% of 41 treated; 11% of evaluable patients) had
partial response. Fifteen patients (37% of 41) had stable
disease as best response and 19 (46% of 41) achieved clinical
benefit. Median progression-free survival was 15.1 weeks
(95% confidence interval [CI]: 8.1–16.7); median overall
survival was 61.0 weeks (95% CI: 56.7–not evaluable).
Most frequent common terminology criteria for adverse
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events grade 3 treatment-related adverse events were diar-
rhea (24.4%) and rash (9.8%). Afatinib monotherapy was
associated with promising clinical activity in extensively
pretreated HER2-positive breast cancer patients who had
progressed following trastuzumab treatment.
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Introduction
Hyperactivation of the ErbB signaling network has been
observed in a variety of malignancies and is associated with
tumor cell proliferation and metastasis [1, 2]. The ErbB
receptor family consists of four receptor tyrosine kinases:
epidermal growth factor receptor (EGFR), also known as
human epidermal growth factor receptor (HER)1 or ErbB1,
HER2 (neu/ErbB2), HER3 (ErbB3), and HER4 (ErbB4) [1].
Increased understanding of the role of the ErbB receptor
signaling network in cancer has led to development of var-
ious agents designed to specifically target these receptors
[3]. Prominent examples include ErbB receptor targeting
monoclonal antibodies such as trastuzumab, and small-
molecule inhibitors such as gefitinib, erlotinib, and lapatinib.
Trastuzumab, a humanized monoclonal antibody directed
against the extracellular domain of the HER2 receptor, is
indicated for the treatment of HER2-positive breast cancer
(BC) in the adjuvant and metastatic setting [4]. However,
both primary and acquired resistance are significant clinical
problems [5]. Resistance to trastuzumab has been described
to occur through many different mechanisms [6–8]. One
such mechanism, molecular plasticity of the ErbB pathway
axis (HER reprogramming), is commonly observed; some
breast tumors switch to alternative HER2 translation
resulting in amino-terminally truncated HER2 fragments
(611-CTF) [9] which are no longer recognized by the anti-
body. In time, trastuzumab may fail to inhibit generation of
p95HER2 [10], a proteolytic fragment which lacks the
extracellular trastuzumab-binding domain and, when pres-
ent, correlates with resistance to trastuzumab [11]. Increased
expression of ErbB family members and cognate ligands
such as EGFR/HER1 and EGF, TGFa, Hb-EGF, and
heregulin has been demonstrated as a mechanism for
acquired resistance to trastuzumab [12] and long-term
trastuzumab exposure of primary resistant breast cancer cells
is associated with HER1 reprogramming [13]. Due to the
presence of HER reprogramming and other resistance
mechanisms in HER2-positive BC, inhibition of more than
one member of the ErbB family is expected to improve
efficacy in this cancer setting. As such, inhibition of more
than one member of the ErbB family may maximize inhi-
bition of ErbB signaling with the potential to improve effi-
cacy of targeted ErbB inhibitors.
Afatinib is a novel, potent, small-molecule tyrosine
kinase inhibitor (TKI) which irreversibly and selectively
targets the ErbB family of receptors: ErbB1 (EGFR/HER1)
(IC50 0.5 nM) and ErbB2 (HER2) (IC50 14 nM) [14].
In vitro studies have shown that afatinib treatment inhibits
growth of the trastuzumab-resistant SUM 190 cell line,
which over expresses HER2 [15, 16] and shows potent
antitumor activity in human xenograft models known to
depend on ErbB signaling [17]. Furthermore, afatinib has
also shown potent antitumor activity in vivo in SUM 190
xenografts, a HER2-positive but trastuzumab-resistant
model known to express large amounts of HER2 and dis-
playing activated EGFR/HER1, HER2, and HER3 [16].
Evidence of clinical activity of afatinib monotherapy
has also been demonstrated in phase I dose-escalation
studies in advanced solid tumors. Stable disease (SD) was
achieved in five of 14 BC patients participating in phase I
monotherapy trials for up to 12 weeks (three patients) and
up to 24 weeks (two patients) [18–20].
This phase II study was conducted to assess the efficacy
and safety of afatinib monotherapy in patients with HER2-
positive metastatic BC after progression on trastuzumab.
Patients and methods
Study design
This phase II, open-label, single-arm, multicenter trial was
conducted in the USA and the UK according to the
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Declaration of Helsinki and in accordance with the Inter-
national Conference on Harmonization Harmonized Tri-
partite Guideline for Good Clinical Practice. Written
informed consent was obtained from all participants.
Treatment
All patients received daily oral doses of afatinib (50 mg/
day) until disease progression, undue adverse events (AEs)
or withdrawal of consent. Dose reduction to 40 mg/day and
consecutively 30 mg/day was required for patients expe-
riencing any Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0 grade C3 drug-related AEs.
Patients with CTCAE grade 3 diarrhea or CTCAE grade 2
diarrhea lasting [7 days despite adequate anti-diarrheal
treatment, persistent CTCAE grade C2 nausea and/or
vomiting despite optimal anti-emetic treatment or persis-
tent CTCAE grade C3 rash despite optimal supportive care
(including systemic antibiotics), were also dose-reduced.
Patients with C20% decrease in left ventricular ejection
fraction (LVEF) from baseline were required to discon-
tinue treatment.
Study population
Adult female patients, aged C18 years, with a confirmed
diagnosis of stage IIIB or IV HER2-positive metastatic BC
(HER2 2? by immunohistochemistry (IHC) and fluores-
cence in situ hybridization-positive or HER2 3? by IHC)
and a life expectancy of C4 months, were included in this
study. Patients were required to have experienced disease
progression following trastuzumab treatment and/or stan-
dard chemotherapy in conjunction with trastuzumab.
Patients with an Eastern Cooperative Oncology Group
(ECOG) performance score of 0–2 and measurable disease
according to Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.0 were included. All patients were
required to have a normal hematological profile and ade-
quate liver, kidney, and bone marrow function, and to have
recovered from any therapy-related toxicity from previous
chemo-, hormone-, immuno- or radiotherapies.
Patients with active infectious disease, gastrointestinal
disorders that may interfere with the absorption of the
study drug, chronic diarrhea or serious illness or concom-
itant non-oncological disease considered incompatible with
study participation by the investigator, or active/symp-
tomatic brain metastases were excluded. Patients receiving
treatment with other investigational drugs, chemo-, hor-
mone-, immuno- or radiotherapy within 4 weeks before the
start of the study (2 weeks for trastuzumab) and patients
who had received previous treatment with an EGFR/HER1-
or HER2-inhibiting agent (except trastuzumab) were also
excluded.
Concomitant medications
Concomitant medications or therapy to provide adequate
care could be given as clinically necessary, although
megestrol acetate and hormonal ablative therapy such as
leuprolide were excluded. Proactive management of diar-
rhea, nausea, vomiting, and rash/acne, was encouraged
using appropriate medications in accordance with the rec-
ommendations for the treatment of AEs provided in the
clinical trial protocol. Treatment with chemo-, hormone-,
immuno- or radiotherapy was not permitted, with the
exception of bisphosphonates and palliative radiotherapy to
non-target lesions.
Efficacy assessments
Tumor assessments were performed after every 8 weeks of
treatment throughout the trial. The primary endpoint in this
trial was objective response [complete response (CR) and
partial response (PR)] as determined by RECIST version
1.0 [21]. Secondary outcome measures included time to
progression, progression-free survival (PFS), overall sur-
vival (OS), time to objective response, and duration of
objective response. In addition, quality of life (QOL) was
measured using the European Organization for Research
and Treatment-Quality of Life Questionnaire (EORTC
QLQ-C30).
Safety and tolerability assessments
The incidence and severity of AEs according to National
Cancer Institute CTCAE version 3.0 were used to assess
safety. Physical examination, vital signs, laboratory
examinations, and cardiac function were regularly moni-
tored. Changes in the selected laboratory parameters were
defined as possibly clinically significant in case of a
worsening from baseline of C2 CTCAE grades.
Pharmacokinetic assessments
For quantification of afatinib plasma concentrations, 5 ml
of venous blood was collected on day 1 of course 1 and day
15 of course 2: pre-dose, 1, 2, and 3 h after drug admin-
istration. In addition, a voluntary pharmacokinetic (PK)
sample could be taken within the time frame of 4–24 h
after afatinib administration. Additional pre-dose plasma
samples were taken on day 15 of course 1 and on day 1 of
course 2 and all subsequent courses. Afatinib drug con-
centrations were determined by a validated high perfor-
mance liquid chromatography–mass spectroscopy (HPLC–
MS/MS) assay.
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Statistical analyses
The analyses in this study were descriptive and explor-
atory. The efficacy analysis included all patients who
received at least one dose of afatinib; in addition, objective
response analyses were based on all patients with evaluable
tumor measurements. Exact 95% Clopper–Pearson confi-
dence intervals (CIs) were calculated for the proportion of
patients showing an objective response to treatment (pri-
mary efficacy outcome). Similar point estimates and exact
CIs were calculated for CR, PR, and SD. PFS, OS, and time
to objective response was estimated from Kaplan–Meier
curves. The safety analysis included all patients who
received at least one dose of trial medication. Safety
findings were summarized using descriptive statistics.
Results
Patient population
This study was conducted at six sites in the USA and six
sites in the UK between November 2006 and August 2009.
In total 52 patients were screened, and 41 patients (21 from
the USA; 20 from the UK) received trial treatment with
afatinib. Baseline demographics for treated patients are
presented in Table 1. Ninety-three percent of patients had
an ECOG performance status of 0–1, and the majority
(92.7%) had undergone prior surgery. All patients had
received prior trastuzumab (as required by the protocol),
with 68.3% of patients receiving this treatment for more
than 1 year (range: 23–396 weeks). The median number of
prior chemotherapy regimens was three. Patients’ best
response to trastuzumab is shown in Table 1. The most
common sites of metastatic disease were lymph nodes,
liver, bone, and lung.
For the 41 patients that received at least one dose of
afatinib, the mean treatment time on afatinib was 99 days.
The majority of patients (73.2%) discontinued due to dis-
ease progression; nine (22.0%) discontinued due to AEs
and two (4.9%) discontinued for other reasons. Twenty
patients (48.8%) required dose reduction to 40 mg, and six
patients (14.6%) had a further reduction from 40 to 30 mg.
Antitumor activity
Of the 41 patients treated with afatinib, 35 patients were
evaluable for objective response (Table 2). Six patients
were not evaluable for response as no baseline or post-
baseline imaging measurements were available, but were
included in the denominator for response and efficacy
assessments. Four patients (10% of 41 patients; 11% of 35
patients evaluable for objective response based on tumor
Table 1 Baseline demographics (treated patients)
Afatinib
(n = 41)
Age (years), median (range) 54 (30–86)




Progesterone receptor-positive, n (%) 12 (29)
Estrogen receptor-positive, n (%) 20 (49)






Best response to trastuzumab, n (%)
Complete response 2 (4.9)
Partial response 13 (31.7)
Stable disease 13 (31.7)
Progressive disease 9 (22.0)
Unknown 2 (4.9)
Not applicable 2 (4.9)
Number of prior chemotherapies
Median 3
Range 0–15





ECOG Eastern Cooperative Oncology Group















(CR ? PR ? SD)
19 46 54 17.1 (7.3–64.0)
PR 4 10 11 12.0 (7.4–56.1)
SD 15 37 43 –
Progressive disease 16 39 46 –
RECIST Response Evaluation Criteria in Solid Tumors, CR complete
response, PR partial response, SD stable disease
a Six patients were not evaluable for response as no post-baseline
imaging measurements were available
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measurement) achieved a PR and no CRs were observed.
Three patients had a PR after 8 weeks while one patient
had a PR after 16 weeks. The median (range) duration of
PR was 12.0 (7.4–56.1) weeks. In one patient, a 30-year
old white female with poorly differentiated infiltrating
ductal breast carcinoma and lung metastases, PR was
maintained for 56 weeks (Table 2) and the duration of
overall clinical benefit in this patient was 64 weeks at
which time the patient developed a new lesion. An addi-
tional 15 patients (37% of 41 patients; 43% of 35 patients)
had SD of whom eight patients achieved SD for[4 months
and three patients achieved SD for 6–12 months. The
maximum duration of SD was 32 weeks.
Overall, 19 patients (46% of 41 patients) were classed as
having achieved clinical benefit (CR or PR or SD) with a
median (range) duration of clinical benefit of 17.1
(7.3–64.0) weeks. A total of 30 patients had available
tumor diameter measurements as depicted in the waterfall
plot (Fig. 1). Of the 15 evaluable patients with SD, nine
patients demonstrated a decrease in tumor size which did
not reach the 30% threshold for PR.
In the total population the median PFS was 15.1 weeks
(Fig. 2; 95% CI: 8.1–16.7) and a total of 14 patients were
known to have died during, or after, the study. The median
OS was 61.0 weeks (95% CI: 56.7–not evaluable) (Fig. 3).
Safety and tolerability
Forty patients (97.3%) experienced treatment-related AEs
(according to CTCAE version 3.0) during treatment. The
most common treatment-related AEs were diarrhea (90.2%),
rash (65.9%), and fatigue (41.5%). Most AEs reported were
mild to moderate in severity (CTCAE grade 1 or 2). Treat-
ment-related AEs occurring in more than 5% of patients, or
with a CTCAE grade 3, are shown in Table 3.
A total of five patients (12%) experienced serious treat-
ment-related AEs: one patient experienced CTCAE grade 3
dehydration and hyponatremia, one patient experienced
CTCAE grade 3 dehydration, diarrhea, and nausea, one
patient experienced CTCAE grade 3 nausea and vomiting,
one patient experienced CTCAE grade 2 vomiting and one
patient experienced CTCAE grade 3 rash, a biopsy of which
showed features of a leukocytoclastic vasculitis.
No clinically significant changes indicative of an
adverse effect of afatinib were observed in LVEF, or
electrocardiogram, or for any laboratory parameter asses-
sed including blood chemistry and liver function tests.
Fig. 1 Best RECIST response*.
*30 patients had available tumor
diameter measurements; five
patients had no tumor diameter
measurements available (two
patients had fewer lesions
measured than at baseline, three




Criteria in Solid Tumors
Fig. 2 Progression-free survival (treated set)
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Other endpoints
ECOG performance score improved during the course of
treatment in 24 (60.0%) patients and remained stable in 15
(37.5%) patients; only one (2.5%) patient had an ECOG status
that deteriorated. Thirty-nine of the 41 patients were assessed
for QOL. Of these, the overall QOL score improved in 15
(38.5%) patients, remained stable in 18 (46.2%) patients and
deteriorated in five (12.8%) patients, based on the best post-
baseline response. One patient had only baseline data avail-
able and was classified as missing. Notable changes in the
QOL functional and symptom scales included improvements
in the domains of fatigue, insomnia, and pain, with approxi-
mately half of all patients recording an improvement in QOL
in these areas; QOL with respect to the occurrence of diarrhea
was noted as deteriorating in 12 of 39 (30.8%) patients.
Pharmacokinetics
The starting dose used in this study was 50 mg afatinib;
dose reductions to 40 or 30 mg were permitted during
treatment and therefore no single-dose PK data were
available for these dose levels. Four patients who provided
data for PK analysis received a dose of 30 mg afatinib. As
such, only PK data from patients receiving 50 or 40 mg
afatinib were considered in the PK analysis.
Afatinib plasma concentrations were in steady-state at
day 15 (obtained by visual inspection). Steady-state may
have been attained earlier, but no PK sampling was per-
formed between days 1 and 15. Trough concentrations
were higher in patients receiving afatinib 50 mg compared
to those receiving 40 mg afatinib (Supplementary Table
S1) and remained stable over the observation period. The
overall variability in afatinib trough plasma concentrations
was moderate to high (gCV values of 30.7–75.1%; Sup-
plementary Table S1).
Discussion
This phase II study was designed to assess the efficacy and
safety of afatinib in patients with HER2-positive metastatic
BC after failure of treatment with trastuzumab. Afatinib
demonstrated antitumor activity in this patient group with
confirmed PRs and durable SD: 19 patients achieved
Fig. 3 Overall survival (treated set)
Table 3 Drug-related adverse events according to CTCAE grade






Grade 1 Grade 2 Grade 3
Number of patients 41 41 41 41
Total with related
AEs
40 (97.6) 3 (7.3) 17 (41.5) 20 (48.8)
Diarrhea 37 (90.2) 18 (43.9) 9 (22.0) 10 (24.4)
Rash 27 (65.9) 7 (17.1) 16 (39.0) 4 (9.8)
Fatigue 17 (41.5) 10 (24.4) 7 (17.1) 0 (0.0)
Nausea 16 (39.0) 9 (22.0) 6 (14.6) 1 (2.4)
Stomatitis 15 (36.6) 6 (14.6) 6 (14.6) 3 (7.3)
Vomiting 14 (34.1) 5 (12.2) 6 (14.6) 3 (7.3)
Dry mouth 8 (19.5) 8 (19.5) 0 (0.0) 0 (0.0)
Anorexia 7 (17.1) 3 (7.3) 4 (9.8) 0 (0.0)
Dermatitis acneiform 7 (17.1) 4 (9.8) 3 (7.3) 0 (0.0)
Epistaxis 7 (17.1) 7 (17.1) 0 (0.0) 0 (0.0)
Dry skin 6 (14.6) 5 (12.2) 1 (2.4) 0 (0.0)
Dysgeusia 6 (14.6) 6 (14.6) 0 (0.0) 0 (0.0)
Mucosal
inflammation
5 (12.2) 3 (7.3) 1 (2.4) 1 (2.4)
Oral pain 5 (12.2) 4 (9.8) 1 (2.4) 0 (0.0)
Pruritus 5 (12.2) 4 (9.8) 0 (0.0) 1 (2.4)
Skin fissures 5 (12.2) 2 (4.9) 2 (4.9) 1 (2.4)
Anemia 4 (9.8) 1 (2.4) 2 (4.9) 1 (2.4)
Dehydration 4 (9.8) 0 (0.0) 2 (4.9) 2 (4.9)
Alopecia 3 (7.3) 3 (7.3) 0 (0.0) 0 (0.0)
Dyspnea 3 (7.3) 2 (4.9) 1 (2.4) 0 (0.0)
Headache 3 (7.3) 3 (7.3) 0 (0.0) 0 (0.0)
Keratoconjunctivitis
sicca
3 (7.3) 2 (4.9) 1 (2.4) 0 (0.0)
Pain in extremity 3 (7.3) 1 (2.4) 2 (4.9) 0 (0.0)
Skin reaction 2 (4.9) 0 (0.0) 1 (2.4) 1 (2.4)
Hyponatremia 1 (2.4) 0 (0.0) 0 (0.0) 1 (2.4)
Leukocytoclastic
vasculitis




1 (2.4) 0 (0.0) 0 (0.0) 1 (2.4)
Vertigo 1 (2.4) 0 (0.0) 0 (0.0) 1 (2.4)
CTCAE common terminology criteria for adverse events, AE adverse
event
a No drug related CTCAE grade 4 events were reported
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clinical benefit (46% of 41 patients), with four patients
(10% of 41 patients) achieving a PR. A total of 15 patients
maintained SD with nine of these patients demonstrating a
reduction in tumor size. The median duration of clinical
benefit was 17.1 weeks. Median PFS was 15.1 weeks and
median OS was 61.0 weeks. This was a heavily pretreated
population; the median number of prior chemotherapy
regimens was three and nearly 70% of patients had
received prior trastuzumab therapy for C12 months, with
36.6% of these patients reporting a CR or PR on trast-
uzumab. With the caveat that this study was a single-arm,
phase II monotherapy trial with a limited number of
patients, these results are interesting when compared to
those obtained upon dual HER2-blockade with lapatinib
and trastuzumab in a randomized phase II trial in a similar
population [22]. Here, the reported PFS was 12.0 weeks
and OS was 51.6 weeks for the combination compared to
8.1 and 39.0 weeks for lapatinib alone. No significant
difference was observed in overall response rate for the
combination arm compared to the monotherapy arm (10.3
vs. 6.9%; P = 0.46). Data reported here with afatinib
confirm preliminary results from ongoing studies showing
that resistance to trastuzumab can be circumvented by
EGFR/HER1 and HER2 targeted TKI therapy. In addition
to the antitumor effects of afatinib, ECOG status and QOL
assessments also improved during the study, further sup-
porting the benefits of treatment.
Although cross-trial comparisons are limited by meth-
odological differences in study design, patient population
and other clinical factors, the results reported in this mono-
therapy trial are encouraging in relation to effects of other
HER2 and EGFR/HER1 inhibitors in similar populations of
patients with HER2-positive metastatic BC. Lapatinib, a
reversible EGFR/HER1 and HER2 TKI, has shown modest
activity in patients with HER2-positive metastatic BC
(n = 104) who have received C3 lines of prior anticancer
therapy and trastuzumab therapy [23]. Burstein and col-
leagues reported an overall response rate of 4.3% (95% CI:
1.6–9.1), clinical benefit rate of 5.7% (95% CI: 2.5–10.9),
and median PFS of 9.1 weeks (95% CI: 8.0–13.6) with la-
patinib monotherapy. With neratinib, an irreversible inhib-
itor of EGFR/HER1 and HER2, an objective response rate of
24% (95% CI: 14–36) with a median PFS of 22.3 weeks was
reported in patients with HER2-positive metastatic BC
(n = 66) who have received prior trastuzumab [24].
As noted previously, more recently the effects of dual
HER2-blockade have been investigated by Blackwell and
colleagues [22]. A phase I trial of assessing the safety and
preliminary antitumor activity of afatinib in combination
with trastuzumab in patients with advanced HER2-positive
BC is ongoing.
Afatinib showed a manageable side effect profile in this
study. Similar to previous studies with afatinib, the most
frequently reported AEs were diarrhea and rash [18, 19, 25,
26]. These AEs were generally manageable with appro-
priate treatment pause, supportive care, and dose reduc-
tions. Early and pre-emptive management of diarrhea is
crucial to prevent potential complications. Most AEs
reported with afatinib were mild to moderate in severity
(CTCAE grade 1 or 2); no CTCAE grade 4 treatment-
related AEs occurred in this study and no treatment-related
deaths were reported. In general, the tolerability profile of
afatinib reported here was similar to that of EGFR TKIs
and consistent with that expected with this class of agent
[27].
Cardiotoxicity is a potential issue for patients treated
with trastuzumab and it has been suggested to be a class
effect for HER2-targeting agents. Therefore, LVEF moni-
toring is conducted in all afatinib clinical trials. No sig-
nificant cardiac safety issues were observed in this study.
The PK characteristics of afatinib have previously been
evaluated in phase I dose escalation studies, performed in
cancer patients and have indicated oral bioavailability and
moderately fast absorption [19, 25, 26, 28–30]. Following
oral administration, maximum concentrations of afatinib
(Cmax) are generally observed 1–6 h (tmax) post-dose, either
after single dose or at steady-state [19, 25, 26, 28]; steady-
state is typically reached within 8 days after first admin-
istration. The PK findings reported here in patients with
advanced metastatic BC appear similar. In this study there
was no detectable change (increase or decrease) in afatinib
plasma concentrations with long-term treatment.
In summary, treatment with afatinib showed promising
clinical activity in HER2-positive BC patients who had
progressed following treatment with trastuzumab. Afatinib
has a manageable AE profile with frequent cutaneous AEs
and diarrhea. Further clinical trials of afatinib in this
patient population are planned.
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